Page 123 - 《中国药房》2025年10期

ting Standards 2022（CHEERS 2022）statement：updated meta-analysis of anticoagulation strategies for venous
reporting guidance for health economic evaluations[J]. thromboembolism in patients with cancer[J]. J Thromb
Value Health，2022，25（1）：3-9. Thrombolysis，2021，51（1）：102-111.
[11] AMIN A，NAEEM M O，AMIN L，et al. Apixaban versus [23] CAPUTO R，PYLE J，KURIAKOSE P，et al. A systematic
low molecular weight heparin in patients with cancer- review of apixaban in prevention and treatment of cancer-
associated venous thromboembolism：a systematic review associated venous thromboembolism[J]. J Am Pharm
and meta-analysis[J]. Ann Med Surg（Lond），2024，86 Assoc（2003），2021，61（5）：e26-e38.
（8）：4675-4683. [24] YAN Y D，DING Z，PAN M M，et al. Net clinical benefit
[12] FUJISAKI T，SUETA D，YAMAMOTO E，et al. Com- of direct oral anticoagulants in patients with cancer and
paring anticoagulation strategies for venous thromboembo‐ venous thromboembolism：a systematic review and trade-
lism associated with active cancer：a systematic review off analysis[J]. Front Cardiovasc Med，2020，7：586020.
and meta-analysis[J]. JACC CardioOncol，2024，6（1）： [25] XIN Z C，LIU F，DU Y，et al. Primary prophylaxis for
99-113. venous thromboembolism in ambulatory cancer patients：a
[13] 李雪梅，徐文坚，卢铨广. 新型口服抗凝药治疗肿瘤相关 systematic review and network meta-analysis[J]. Ann Pal‐
静脉血栓栓塞症网状 Meta 分析[J]. 中国药业，2024，33 liat Med，2020，9（5）：2970-2981.
（1）：116-122. [26] FUENTES H E，MCBANE R D，WYSOKINSKI W E，et
[14] NING H Y，YANG N N，DING Y Y，et al. Efficacy and al. Direct oral factor Ⅹa inhibitors for the treatment of acute
safety of direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism：a systematic
cancer-associated venous thromboembolism：a systematic review and network meta-analysis[J]. Mayo Clin Proc，
review and Bayesian network meta-analysis[J]. Med Clin 2019，94（12）：2444-2454.
（Barc），2023，160（6）：245-252. [27] WU Y，YIN T C，JIAN G L，et al. Cost-effectiveness
[15] 李朋，何虎强，陈豪，等. 阿哌沙班治疗和预防癌症相关 analysis of direct oral anticoagulants versus low-
静脉血栓栓塞症的疗效与安全性的 Meta 分析[J]. 中华 molecular-weight heparin and no thromboprophylaxis in
血管外科杂志，2023，8（4）：354-361. primary prevention of cancer-associated venous throm-
[16] ARCE-HUAMANI M A，BARBOZA J J，MARTÍNEZ- boembolism in China[J]. Front Pharmacol，2024，15：
HERRERA J F，et al. Efficacy and safety of apixaban ver‐ 1373333.
sus dalteparin as a treatment for cancer-associated venous [28] GULATI S，ECKMAN M H. Anticoagulant therapy for
thromboembolism：a systematic review and meta-analysis cancer-associated thrombosis：a cost-effectiveness analysis
[J]. Medicina（Kaunas），2023，59（10）：1867. [J]. Ann Intern Med，2023，176（1）：1-9.
[17] BALOCH M F，ADEPOJU A V，FALKI V，et al. Com‐ [29] BELL S，ORELLANA T，GARRETT A，et al. Prophylac‐
parative efficacy of oral apixaban and subcutaneous low tic anticoagulation after minimally invasive hysterectomy
molecular weight heparins in the treatment of cancer- for endometrial cancer：a cost-effectiveness analysis[J].
associated thromboembolism：a meta-analysis[J]. Cureus， Int J Gynecol Cancer，2023，33（12）：1875-1881.
2023，15（8）：e43447. [30] MUÑOZ A J，ORTEGA L，GUTIÉRREZ A，et al. Cost-
[18] SAMARANAYAKE C B，ANDERSON J，MCCABE C， effectiveness of apixaban and rivaroxaban in thrombopro‐
et al. Direct oral anticoagulants for cancer-associated ve‐ phylaxis of cancer patients treated with chemotherapy in
nous thromboembolisms：a systematic review and network Spain[J]. J Med Econ，2023，26（1）：1145-1154.
meta-analysis[J]. Intern Med J，2022，52（2）：272-281. [31] MUÑOZ A，GALLARDO E，AGNELLI G，et al. Cost-
[19] RIAZ I B，FUENTES H E，NAQVI S A A，et al. Direct effectiveness of direct oral anticoagulants compared to
oral anticoagulants compared with dalteparin for treatment low-molecular-weight-heparins for treatment of cancer
of cancer-associated thrombosis：a living，interactive sys‐ associated venous thromboembolism in Spain[J]. J Med
tematic review and network meta-analysis[J]. Mayo Clin Econ，2022，25（1）：840-847.
Proc，2022，97（2）：308-324. [32] KIMPTON M，KUMAR S，WELLS P S，et al. Cost-utility
[20] WU S Y，LV M N，CHEN J N，et al. Direct oral anticoagu‐ analysis of apixaban compared with usual care for primary
lants for venous thromboembolism in cancer patients：a thromboprophylaxis in ambulatory patients with cancer[J].
systematic review and network meta-analysis[J]. Support CMAJ，2021，193（40）：E1551-E1560.
Care Cancer，2022，30（12）：10407-10420. [33] GLICKMAN A，BRENNECKE A，TAYEBNEJAD A，et
[21] BRANDÃO G M S，MALGOR R D，VIECELI T，et al. A al. Cost-effectiveness of apixaban for prevention of venous
network meta-analysis of direct factor Ⅹa inhibitors for the thromboembolic events in patients after gynecologic
treatment of cancer-associated venous thromboembolism cancer surgery[J]. Gynecol Oncol，2020，159（2）：476-482.
[J]. Vascular，2022，30（1）：130-145. （收稿日期：2024-11-20 修回日期：2025-04-07）
[22] UEYAMA H，MIYASHITA H，TAKAGI H，et al. Network （编辑：陈 宏）

中国药房 2025年第36卷第10期 China Pharmacy 2025 Vol. 36 No. 10 · 1265 ·